Related Experiment Video
Updated: Jun 26, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[A retrospective analysis of clinical outcomes in 225 childhood with acute lymphoblastic leukemia]
Xiao-Juan Chen1, Li Zhang, Tian-Feng Liu
1Institue of Hematology and Blood Diseases Hospital, CAMS, Tianjin 300020, China.
Objective:
To retrospectively analyze the outcomes in newly diagnosed children with acute lymphoblastic leukemia (ALL).
Methods:
Two hundred and twenty-five children with ALL (from Jan 2003 to Dec 2006) were divided into high-(HR) and standard-risk (SR) groups according to cytomorphology, immunology, cytogenetics and molecular biology (MICM) finding. SR patients were treated with conventional therapy, while HR patients with additional high-dose (HD) methotrexate (MTX) (5 g/m(2)) and early mid-dose cytarabine (Ara-C) (1 g/m(2), q 12 h x 3 d). All patients took maintenance chemotherapy of MM+VP. Respond rate (RR) and overall survival (OS) rate of patients were retrospectively analyzed.
Results:
The probabilities of 3-year and 5-year OS were 79.0% and 72.6%, respectively. The SR patients had a remarkably higher 3-year OS (87.6%) than that of HR patients (66.1%) (P = 0.002).
Conclusion:
(1) Early intensive therapy with mid-dose Ara-C and HD-MTX significantly improves the outcome of HR children with ALL. (2) The early intensive therapy in HR patients reduces the incidence of CNSL. (3) Periodic intensification and more re-induction therapies in SR patients remarkably improves the long-term survival.
